Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction

American Heart Journal

Volumn 138, Issue 4 I, 1999, Pages 696-704

  Fung, A Y ^a   Lorch, G ^a   Cambier, P A ^a   Hansen, D ^a   Titus, B G ^a   Martin, J S ^a   Lee, J J ^a   Every, N R ^a   Hallstrom, A P ^a   Stock Novack, D ^a   Scherer, J ^a   Weaver, W D ^a   Brady, J ^a   Gray, P ^a   Hess, J ^a   McBride, R ^a   Reynold Haertle, R ^a   Scheinbaum, S ^a   Wirkus, M ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; EFEGATRAN; HEPARIN; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; BLOOD VESSEL COMPLIANCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FATALITY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0032886670     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70185-7     Document Type: Article

References (18)

1. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-22.
2. GUSTO Investigators. An international randomized trial comparing 4 thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
3. Simes R, Topol R, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Circulation 1995;91:1923-8.
4. Topol E. Potential for a new coronary thrombolytic plateau. J Thromb Thrombolysis 1996;3:127-34.
5. Weitz J, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91.
6. Loscalzo J. Thrombin inhibitors in fibrinolysis: a Hobson's choice of alternatives. Circulation 1996;94:863-5.
7. Jackson C, Crowe V, Bailey B, et al. Conjunctive therapy with the thrombin inhibitor, LY294468, and aspirin produced enhanced anti-reocclusive activity when used in a canine model of streptokinase-induced coronary thrombolysis [abstract]. Pharmacologist 1993;35:407.
8. Theroux P, Perez-Villa F, Waters D, et al. Randomized doubleblind comparison of 2 doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarctrelated artery in acute myocardial infarction. Circulation 1995;91:2132-9.
9. Cannon C, McCabe C, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.
10. TIMI Investigators. TIMI special report: the thrombolysis in myocardial infarction (TIMI) trial: phase 1 findings. N Engl J Med 1985;312:932-6.
11. Gibbons R. Perfusion imaging with 99m-Tc-sestamibi for the assessment of myocardial area at risk and the efficacy of acute treatment in myocardial infarction. Circulation 1991;83(3 suppl):137-42.
12. O'Conner M, Hammel T, Gibbons R. In vitro validation of a simple tomographic technique for estimation of percentage myocardium at risk using methoxyisobutyl isonitrile technetium 99m (sestamibi). Eur J Nucl Med 1990;17:69-76.
13. Cheseboro JH. Direct thrombin inhibition superior to heparin during and after thrombolysis: dose, duration, and drug. Circulation 1997;96:2118-20.
14. White H, Aylward P, Frey M, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155-61.
15. Ohman E, Slovak J, Anderson RL, et al. Potential inhibition of thrombin with efegatran in combination with tPA in acute myocardial infarction: results of a multicenter randomized dose ranging trial [abstract]. Circulation 1996;94:I-430.
16. GUSTO 2b Investigators. A Comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
17. Metz B, Granger C, White H, et al. Streptokinase and hirudin reduces death and reinfarction in acute myocardial infarction compared with streptokinase and heparin: results from GUSTO IIb [abstract]. Circulation 1996;94:I-43.
18. Antman E, for the TIMI 9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-21.